Humana has “entered a new joint venture agreement” with a BlackRock investment unit to manage and operate its network of 150 CenterWell primary care clinics.
HUM Humana Inc.
XNYS
425.29
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HUM
$425.29
—
Key stats
$425.29
- 52-Week Range
- $163.11 – $456.50
- YTD
- +60.80%
- IV Rank (30D)
- 31.81
- Straddle Price
- $47.65
- P/C Vol Ratio
- 0.66
- Market Cap
- $51.3B
- Open
- $431.52
- Day Range
- $423.85 – $434.12
- Volume
- 1,561,283
- Prev Close
- $427.38
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.09% |
| Beta vs SPY | 0.64 |
| Cost of Equity (CAPM) | 8.30% (VRP-adj) |
| WACC | 7.74% |
| Volatility Risk Premium | +47.3pp (IV − HV30) |
| Effective Tax Rate | 17.8% |
| Rev. Growth (YoY, DCF input) | +26.7% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.9B |
| Return on Equity (TTM) | 6.7% |
| Book / Price | 37.3% — banking bias active (P/B is primary) |
| Bank Quality Adj | ×0.50 (target ROE vs peer median) |
| Gross Margin (TTM) | 13.3% |
| FCF Margin (TTM) | 1.3% |
| Debt / Equity | 0.74 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | +12.7% (reverse-DCF on current price) |
| SMA 50 | $395.35 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $403.60 |
| Bollinger Width / SMA20 | 4.8% (drives anchor stability) |
| Net Debt | $7.4B |
| Market Cap | $52B |
Peers used for multiples: CI, CNC, ELV, UNH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
74%
20-Day Fair Value
≈ by Nov 19, 2026
$428.52
α +0.7%
rank 37%
conviction
46%
40-Day Fair Value
≈ by Dec 18, 2026
$438.48
α +3.1%
rank 29%
conviction
85%
60-Day Fair Value
≈ by Jan 18, 2027
$435.77
α +2.4%
rank 31%
conviction
74%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $784.19 | 20% | |
| DDM (Gordon) | $112.60 | 0% | |
| Peer P/E | $109.50 | 6% | median 18.8× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 11.0× · 4 peers |
| Peer P/B | $313.47 | 9% | median 2.0× · 4 peers |
| Peer P/S | $244.43 | 3% | median 0.4× · 4 peers |
| Market Anchor (SMA50) | $395.35 | 41% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $429.80 | 20% | 69 strikes · skew +0.27 |
As of 2026-10-21 · updated
Related
About
- Industry (SIC)
- HOSPITAL & MEDICAL SERVICE PLANS (6324) · industry map
- Exchange
- XNYS
- Market Cap
- $51.3B
- Employees
- 67,060
- List Date
- 1971-05-18
- CIK
- 0000049071
- Next Earnings
- 2026-11-06 (Pre-Market)
- EPS Forecast
- ($1.03) (10 est.)
- Headquarters
- Louisville, KY
- Homepage
- https://www.humana.com
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -7.05% | -15.67% | 2.24% | -19.58% | 16.06% | -26.19% | -8.37% |
| Feb | -0.07% | 11.17% | -3.56% | -6.79% | -7.71% | 1.78% | -0.86% |
| Mar | 8.92% | 0.97% | -2.15% | -1.51% | 1.17% | -7.42% | -0.00% |
| Apr | 7.85% | 0.71% | 3.97% | -14.04% | -0.94% | 33.62% | 5.19% |
| May | -2.86% | 4.78% | -6.22% | 13.97% | -8.95% | 30.73% | 5.24% |
| Jun | 2.66% | 4.58% | -13.20% | 2.59% | 5.66% | 20.99% | 3.88% |
| Jul | -4.86% | 0.63% | 2.37% | -3.18% | -1.07% | -11.63% | -2.96% |
| Aug | -5.62% | 1.50% | 0.77% | -1.26% | 22.81% | 2.33% | 3.42% |
| Sep | -4.06% | -0.37% | 5.63% | -12.87% | -16.09% | -3.37% | -5.19% |
| Oct | 18.29% | 11.72% | 6.50% | -7.74% | 12.73% | 12.05%* | 8.92% |
| Nov | -8.66% | -0.83% | -0.92% | 13.68% | -12.20% | -- | -1.79% |
| Dec | 11.07% | -6.60% | -7.55% | -13.45% | 5.74% | -- | -2.16% |
| Total | 12.49% | 10.00% | -13.20% | -43.90% | 10.19% | 43.92% | 3.25% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $406.13
SMA 50: $396.40
SMA 200: $303.43
Current: $425.42
EMA 12: $416.81
EMA 26: $407.31
MACD: 9.5006 | Signal: 1.6834
BULLISH
ADX (14): 20.96
WEAK TREND
+DI: 29.37
−DI: 21.16
Momentum Oscillators
RSI (14): 58.37
NEUTRAL
Stoch %K: 57.95
Stoch %D: 55.24
Williams %R: -38.54
Volume & Volatility
BB Upper: $443.96
BB Lower: $368.30
NEUTRAL
OBV: 77,030,822
Vol SMA 20: 1,719,459
Vol ROC: -14.59%
ATR: $17.43
True Range: $10.27
HV 20: 53.4%
HV 30: 46.7%
HV 60: 40.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary BULLISH (Confidence Level: 7/10)
Key drivers: Positive earnings expectations, partnership announcements, and increasing institutional interest.
Primary risks: Regulatory issues, competition in the dental insurance market, and potential sector rotation.
Investment thesis: HUM's stock price is likely to continue its upward trend due to a combination of positive factors, including strong technical indicators, favorable news sentiment, and low volatility. However, investors should remain cautious due to potential regulatory or competitive risks.
Recent news sentiment impact: The recent news headlines have had a NEUTRAL sentiment impact on the stock price, with some positive articles (CVS Health Stock Is Soaring) offset by negative news (Humana, Inc. Data Breach).
Technical Analysis Trend Direction: Short-term uptrend (1-4 weeks), Medium-term neutral (1-3 months), Long-term uptrend (3-12 months)
Support/Resistance Levels:
- SMA 20: $335.31
- EMA 12: $355.18
Momentum Signals: RSI: 76.10 (overbought) MACD signal line crossover: Bullish momentum Bollinger Bands position: Neutral, with price touching the upper band
Volume Analysis: Volume SMA 20: 1257650.00 On-Balance Volume (OBV): 41404498.24 Volume Rate of Change: 78.04%
News & Sentiment Analysis Recent Headlines Summary: Positive news on CVS Health, Humana's data breach, and partnerships with Disabled American Veterans.
Sentiment Assessment: POSITIVE overall sentiment
Catalyst Identification:
- Upcoming earnings announcement (no specific date available)
- Potential sector rotation within the healthcare industry
- Regulatory changes or updates on the dental insurance market
Market Narrative: The news headlines have generally been positive, aligning with the technical signals indicating an uptrend.
Risk & Volatility Assessment Beta Interpretation: Low volatility - stock moves less than market (beta: 0.51)
Volatility Regime: Historical volatility levels are relatively low.
Options Market Signals:
- IV Rank: 13.6% (Low)
- Current IV: 50.4%
- Expected Move: $33.35
Downside Protection: Support levels: SMA 20 ($335.31), EMA 12 ($355.18)
Market Context & Positioning Sector Performance: Healthcare sector has been performing well, with HUM's stock price increasing in line with the overall trend.
Institutional Activity: Volume patterns suggest institutional interest and accumulation.
Correlation Analysis: HUM's stock moves relatively less than the market (R-squared interpretation).
Relative Valuation: Position within a trading range, with potential for further growth.
Key Levels & Action Items Critical Price Levels:
- SMA 20 ($335.31)
- EMA 12 ($355.18)
Breakout/Breakdown Levels:
- Upper Bollinger Band: $391.78
- Lower Bollinger Band: $278.85
Time-Sensitive Catalysts:
- Upcoming earnings announcement (no specific date available)
- Potential sector rotation within the healthcare industry
- Regulatory changes or updates on the dental insurance market
Risk Management: Stop-loss levels: SMA 20 ($335.31) and EMA 12 ($355.18)
Overall, this analysis suggests a bullish outlook for HUM's stock price, with a confidence level of 7/10. The technical indicators indicate an uptrend, while the news sentiment has been generally positive. However, investors should remain cautious due to potential regulatory or competitive risks and consider setting stop-loss levels at SMA 20 and EMA 12.
Generated
News
All HUM news →
On Oct. 9, 2026, major benchmarks recover from earlier volatility as AI jitters and geopolitical tensions ease.
On this episode of Stock Movers: - Delta (DAL) shares are sliding after the company reduced its full-year earnings outlook due to high jet fuel prices stemming from the war in the Middle East. - Humana (HUM) is surging as the company improved its performance on crucial Medicare…
Showing 1–10 of 23
Page 1 of 3
Earnings History
17 of 23 under expected move
Avg Expected Move
5.48%
Avg Actual Move
4.16%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-03 | Pre-Market | 4.19% | 0.78% | 0.19x | Within |
| 2021-04-28 | Pre-Market | 2.96% | 2.27% | 0.77x | Within |
| 2021-07-28 | Pre-Market | 3.22% | 5.71% | 1.77x | Exceeded |
| 2021-11-03 | Pre-Market | 3.23% | 0.51% | 0.16x | Within |
| 2022-02-02 | Pre-Market | 3.74% | 2.70% | 0.72x | Within |
| 2022-04-27 | Pre-Market | 4.50% | 2.99% | 0.66x | Within |
| 2022-07-27 | Pre-Market | 3.75% | 2.83% | 0.75x | Within |
| 2022-11-02 | Pre-Market | 3.89% | 0.92% | 0.24x | Within |
| 2023-02-01 | Pre-Market | 3.88% | 0.31% | 0.08x | Within |
| 2023-04-26 | Pre-Market | 3.16% | 0.75% | 0.24x | Within |
| 2023-08-02 | Pre-Market | 4.43% | 5.60% | 1.26x | Exceeded |
| 2023-11-01 | Pre-Market | 3.80% | 6.56% | 1.73x | Exceeded |
| 2024-01-18 | Pre-Market | 1.62% | 7.99% | 4.93x | Exceeded |
| 2024-04-24 | Pre-Market | 5.95% | 3.66% | 0.62x | Within |
| 2024-07-31 | Pre-Market | 6.30% | 10.61% | 1.68x | Exceeded |
| 2024-10-30 | Pre-Market | 7.10% | 3.32% | 0.47x | Within |
| 2025-02-11 | Pre-Market | 7.44% | 3.55% | 0.48x | Within |
| 2025-04-30 | Pre-Market | 9.27% | 1.11% | 0.12x | Within |
| 2025-07-30 | Pre-Market | 8.38% | 12.40% | 1.48x | Exceeded |
| 2025-11-05 | Pre-Market | 7.45% | 6.01% | 0.81x | Within |
| 2026-02-11 | Pre-Market | 10.95% | 3.25% | 0.30x | Within |
| 2026-04-29 | Pre-Market | 8.23% | 5.83% | 0.71x | Within |
| 2026-07-29 | Pre-Market | 8.55% | 5.99% | 0.70x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
HUM Options Activity & IV Rank
HUM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 49.2%
7-DTE IV: 43.3%
Expected Move: $47.65
7-DTE Move: $22.90
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 990
Put Volume: 652
P/C Volume: 0.659
BULLISH
Call OI: 8,396
Put OI: 11,089
P/C OI: 1.321
Total OI: 19,485
ATM Options Pricing
ATM Call: $24.00
ATM Put: $23.65
Call %: 5.6%
Put %: 5.6%
Chain Summary
Chain Volume: 15,021
Chain OI: 129,779
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 69th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
69%
vs own history
GEX tilt
+0.20
OI-weighted, today
Vanna tilt
+0.64
δ-sensitivity to IV
Charm tilt
-0.67
δ-decay vs time
Vanna tilt +0.64: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.67: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 238 ATM contracts, 40k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
15%
-0.7
pts
EXTREME
as of Oct 21 · ATM 54.1% / Wing 53.4%
30 DTE / 10d
11%
+0.1
pts
EXTREME
as of Oct 21 · ATM 49.2% / Wing 49.3%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)13.2LowOct 21
IV Rank (30 DTE)31.8MediumOct 21
Straddle Price (30 DTE)$47.65Oct 21
Beta Analysis
Risk Metrics
Beta: 0.6236
Alpha: 38.59%
Correlation: 0.1689
R-Squared: 2.9%
Stock Volatility: 46.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own HUM
8 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $178.4M | #224 of 6285 | +217.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $140.1M | #225 of 3716 | +213.2% | 13F | |
| Glenview Capital Hedge fund Larry Robbins | $101.0M | #16 of 42 | -24.1% | 13F | |
| Point72 Hedge fund Steve Cohen | $39.1M | #391 of 1945 | new | 13F | |
| Soros Fund Management Family office George Soros, Robert Soros, Jonathan Soros | $13.2M | #121 of 251 | -50.9% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $3.6M | #545 of 997 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $3.4M | #1664 of 3138 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1.3M | #1573 of 4729 | -2.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
HUM Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 120,839,500 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
35 filers$2.00B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $399.84M | 19.99% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $363.38M | 18.17% | 2026-06-30 |
| 3 | Goldman Sachs Group Inc Custodian | $232.33M | 11.62% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $207.71M | 10.39% | 2026-06-30 |
| 5 | JPMorgan Chase & Co Custodian | $143.08M | 7.15% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $137.08M | 6.85% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $76.14M | 3.81% | 2025-09-30 |
| 8 | Walleye Trading LLC | $69.47M | 3.47% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $58.51M | 2.93% | 2026-06-30 |
| 10 | Squarepoint Ops LLC | $50.69M | 2.53% | 2026-06-30 |
| 11 | D. E. Shaw & Co., Inc. Custodian | $46.51M | 2.33% | 2026-06-30 |
| 12 | Pentwater Capital Management LP | $39.72M | 1.99% | 2026-06-30 |
| 13 | Jain Global LLC | $23.83M | 1.19% | 2026-06-30 |
| 14 | Millennium Management LLC Custodian | $22.48M | 1.12% | 2026-06-30 |
| 15 | Alphadyne Asset Management LP | $20.38M | 1.02% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $17.84M | 0.89% | 2026-06-30 |
| 17 | Qube Research & Technologies Ltd | $17.72M | 0.89% | 2026-06-30 |
| 18 | Simplex Trading, LLC Custodian | $10.37M | 0.52% | 2026-06-30 |
| 19 | CAPITAL FUND MANAGEMENT S.A. | $9.65M | 0.48% | 2026-06-30 |
| 20 | Barclays PLC Custodian | $7.39M | 0.37% | 2026-06-30 |
| 21 | Point72 Asset Management, L.P. | $7.19M | 0.36% | 2026-06-30 |
| 22 | Cubist Systematic Strategies, LLC | $6.50M | 0.33% | 2025-09-30 |
| 23 | Brevan Howard Capital Management LP | $6.43M | 0.32% | 2026-06-30 |
| 24 | NOMURA HOLDINGS INC | $6.40M | 0.32% | 2026-06-30 |
| 25 | CMT Capital Markets Trading GmbH | $5.76M | 0.29% | 2026-06-30 |
41 filers$1.81B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $423.44M | 23.43% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $310.90M | 17.20% | 2026-06-30 |
| 3 | JPMorgan Chase & Co Custodian | $188.73M | 10.44% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $160.12M | 8.86% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $122.54M | 6.78% | 2026-06-30 |
| 6 | Goldman Sachs Group Inc Custodian | $103.08M | 5.70% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $65.54M | 3.63% | 2026-06-30 |
| 8 | Squarepoint Ops LLC | $56.05M | 3.10% | 2026-06-30 |
| 9 | Wolverine Trading, LLC Custodian | $52.65M | 2.91% | 2025-09-30 |
| 10 | Walleye Trading LLC | $49.57M | 2.74% | 2026-06-30 |
| 11 | Jain Global LLC | $43.69M | 2.42% | 2026-06-30 |
| 12 | Alphadyne Asset Management LP | $29.08M | 1.61% | 2026-06-30 |
| 13 | Barclays PLC Custodian | $26.30M | 1.45% | 2026-06-30 |
| 14 | Millennium Management LLC Custodian | $23.08M | 1.28% | 2026-06-30 |
| 15 | UBS Group AG Custodian | $22.13M | 1.22% | 2026-06-30 |
| 16 | D. E. Shaw & Co., Inc. Custodian | $14.78M | 0.82% | 2026-06-30 |
| 17 | Qube Research & Technologies Ltd | $12.15M | 0.67% | 2026-06-30 |
| 18 | CREDIT AGRICOLE S A | $11.92M | 0.66% | 2026-06-30 |
| 19 | BNP Paribas Financial Markets Custodian | $11.08M | 0.61% | 2026-06-30 |
| 20 | NOMURA HOLDINGS INC | $10.37M | 0.57% | 2026-06-30 |
| 21 | TUDOR INVESTMENT CORP ET AL | $10.13M | 0.56% | 2026-06-30 |
| 22 | Simplex Trading, LLC Custodian | $8.02M | 0.44% | 2026-06-30 |
| 23 | Pentwater Capital Management LP | $7.94M | 0.44% | 2026-06-30 |
| 24 | CAPITAL FUND MANAGEMENT S.A. | $6.12M | 0.34% | 2026-06-30 |
| 25 | CDC Financial, Inc. | $5.96M | 0.33% | 2026-06-30 |
HUM Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Kurt J Hilzinger | Director | Award (A) | — | — | EDGAR | |
| 2026-09-03 | Shantanu Nundy | Chief Medical Officer | Award (A) | +2,549 | — | EDGAR | |
| 2026-08-04 | Frederick John Crawford | Director | Award (A) | +544 | — | EDGAR | |
| 2026-08-04 | Paul John Smith | Director | Award (A) | +544 | — | EDGAR | |
| 2026-07-02 | Kurt J Hilzinger | Director | Award (A) | — | — | EDGAR | |
| 2026-05-05 | Aaron Martin | President, Medicare Advantage | Award (A) | +8,206 | — | EDGAR | |
| 2026-05-05 | Sanjay K Shetty | President, CenterWell | Award (A) | +9,945 | — | EDGAR | |
| 2026-05-05 | Joseph C Ventura | Chief Legal Officer | Award (A) | +10,318 | — | EDGAR | |
| 2026-05-05 | Robert Stuart Field | Director | Award (A) | +852 | — | EDGAR | |
| 2026-05-05 | Michelle A. O'Hara | Chief Human Resources Officer | Award (A) | +10,485 | — | EDGAR | |
| 2026-05-05 | James A. Rechtin | President & CEO | Award (A) | +35,633 | — | EDGAR | |
| 2026-05-05 | David Dintenfass | President, Enterprise Growth | Award (A) | +11,273 | — | EDGAR | |
| 2026-05-05 | Japan Mehta | Chief Information Officer | Award (A) | +9,448 | — | EDGAR | |
| 2026-05-05 | Celeste Mellet | Chief Financial Officer | Award (A) | −15,387 | — | EDGAR | |
| 2026-04-03 | Sanjay K Shetty | President, CenterWell | Mixed | +486 | $175.44 | -$70.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HUM Insider Holdings
29 insiders · @ $425.42
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James A. Rechtin | President & CEO | 67,631 | $28.77M | $1.50M | 9 | 2026-05-05 |
| 2 | Celeste Mellet | Chief Financial Officer | 39,637 | $16.86M | $0 | 5 | 2026-05-05 |
| 3 | Frank A Damelio | Director | 31,852 | $13.55M | $142.0K | 31 | 2026-01-05 |
| 4 | Joseph C Ventura | Chief Legal Officer | 27,699 | $11.78M | -$3.45M | 20 | 2026-05-05 |
| 5 | David Dintenfass | President, Enterprise Growth | 25,407 | $10.81M | $0 | 6 | 2026-05-05 |
| 6 | Aaron Martin | President, Medicare Advantage | 25,237 | $10.74M | $0 | 2 | 2026-05-05 |
| 7 | Susan M Diamond | Chief Financial Officer | 22,384 | $9.52M | -$5.39M | 25 | 2025-01-03 |
| 8 | Sanjay K Shetty | President, CenterWell | 22,088 | $9.40M | $150.0K | 9 | 2026-05-05 |
| 9 | Michelle A. O'Hara | Chief Human Resources Officer | 20,026 | $8.52M | $0 | 5 | 2026-05-05 |
| 10 | Kurt J Hilzinger | Director | 19,448 | $8.27M | $0 | 62 | 2026-10-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HUM Board & Officers
As of SEC filings through Oct 2, 2026Directors 13
- Frank A Damelio · on file since 2006
- Kurt J Hilzinger · on file since 2006
- Karen Katz · since Sep 20, 2019
- John W Garratt · since Feb 19, 2020
- Wayne A.I. Frederick · since Feb 19, 2020
- Raquel C. Bono · since Sep 4, 2020
- Jorge S. Mesquita · since Feb 17, 2021
- Marcy S Klevorn · since Feb 17, 2021
- David T Feinberg · since Mar 1, 2022
- Gordon Smith · since Oct 23, 2024
- Robert Stuart Field · since Apr 16, 2026
- Frederick John Crawford · since Jul 28, 2026
- Paul John Smith · since Jul 28, 2026
Officers 11
- James A. Rechtin · President & CEO · listed since Dec 2024
- Sanjay K Shetty · President, CenterWell · since Mar 27, 2023
- David Dintenfass · President, Enterprise Growth · since Feb 5, 2024
- George Renaudin II · President, Insurance · listed since Dec 2024
- Aaron Martin · President, Medicare Advantage · since Jan 26, 2026
- Celeste Mellet · Chief Financial Officer · since Jan 11, 2025
- Joseph C Ventura · Chief Legal Officer · listed since Dec 2019
- John-Paul W. Felter · SVP, Chief Accting Off & Cont. · since Aug 1, 2022
- Michelle A. O'Hara · Chief Human Resources Officer · since Jan 1, 2025
- Japan Mehta · Chief Information Officer · since Feb 1, 2025
- Shantanu Nundy · Chief Medical Officer · since Aug 31, 2026
Changes in the last 10 years (103)
| Aug 31, 2026 | Shantanu Nundy became Chief Medical Officer |
| Jul 28, 2026 | Paul John Smith became a director |
| Jul 28, 2026 | Frederick John Crawford became a director |
| Apr 16, 2026 | Robert Stuart Field became a director |
| Jan 26, 2026 | Aaron Martin became President, Medicare Advantage |
| Feb 1, 2025 | Japan Mehta became Chief Information Officer |
| Jan 11, 2025 | Celeste Mellet became Chief Financial Officer |
| Jan 3, 2025 | Timothy S. Huval reported in an SEC filing no longer being Chief Administrative Officer |
| Jan 1, 2025 | Michelle A. O'Hara became Chief Human Resources Officer |
| Dec 17, 2024 | James A. Rechtin listed as President & CEO (previously President & COO) in SEC filings |
| Dec 17, 2024 | George Renaudin II listed as President, Insurance (previously President, Medicare & Medicaid) in SEC filings |
| Dec 3, 2024 | The company announced the departure of Susan M Diamond as Chief Financial Officer in an SEC filing |
| Oct 23, 2024 | Gordon Smith became a director |
| Sep 30, 2024 | William Kevin Fleming reported in an SEC filing no longer being Chief Corporate Aff. Officer |
| Jul 1, 2024 | Bruce D Broussard reported in an SEC filing no longer being a director |
| Jul 1, 2024 | Bruce D Broussard reported in an SEC filing no longer being President & CEO |
| Apr 18, 2024 | William J. McDonald reported in an SEC filing no longer being a director |
| Feb 5, 2024 | David Dintenfass became President, Enterprise Growth |
| Jan 8, 2024 | James A. Rechtin became President & COO |
| Dec 19, 2023 | William Kevin Fleming listed as Chief Corporate Aff. Officer (previously Seg Pres, Pharmacy Sol & CCAO) in SEC filings |
| Apr 20, 2023 | James J /ky Obrien reported in an SEC filing no longer being a director |
| Apr 20, 2023 | David A Jr/ky Jones reported in an SEC filing no longer being a director |
| Apr 3, 2023 | Susan D. Schick reported in an SEC filing no longer being Seg Pres. Grp. & Military Bus. |
| Apr 3, 2023 | M.D. Andrew C. Agwunobi reported in an SEC filing no longer being Seg. President, Home Solutions |
| Mar 27, 2023 | Sanjay K Shetty became President, CenterWell |
| Feb 1, 2023 | George Renaudin II became President, Medicare & Medicaid |
| Jan 3, 2023 | Timothy Alan Wheatley reported in an SEC filing no longer being Segment President, Retail |
| Sep 15, 2022 | Brad D Smith became a director |
| Aug 5, 2022 | William H Shrank reported in an SEC filing no longer being Chief Medical Officer |
| Aug 1, 2022 | Michael A. Koeberlein reported in an SEC filing no longer being SVP, Chief Accting Off & Cont. |
| Aug 1, 2022 | John-Paul W. Felter became SVP, Chief Accting Off & Cont. |
| Jun 1, 2022 | Heather Cox reported in an SEC filing no longer being Chief Dig Health & Analyt Off. |
| Apr 21, 2022 | Marissa T Peterson reported in an SEC filing no longer being a director |
| Mar 31, 2022 | Michael A. Koeberlein became SVP, Chief Accting Off & Cont. |
| Mar 31, 2022 | Cynthia H Zipperle reported in an SEC filing no longer being SVP, Chief Acct Officer & Cont |
| Mar 1, 2022 | David T Feinberg became a director |
| Feb 21, 2022 | M.D. Andrew C. Agwunobi became Seg. President, Home Solutions |
| Dec 17, 2021 | William Kevin Fleming listed as Seg Pres, Pharmacy Sol & CCAO (previously Seg Pres, Clin & Phm Solutions) in SEC filings |
| Dec 17, 2021 | William H Shrank no longer listed as a director in SEC filings |
| Dec 17, 2021 | William H Shrank listed as Chief Medical Officer (previously Chief Med & Corp Affairs Off.) in SEC filings |
| Dec 17, 2021 | Samir Deshpande listed as Chief Information Officer (previously Chief Tech & Risk Officer) in SEC filings |
| Sep 1, 2021 | Susan D. Schick became Seg Pres. Grp. & Military Bus. |
| Sep 1, 2021 | Christopher H. Hunter reported in an SEC filing no longer being Seg Pres. Gr. & Military Bus. |
| Jul 6, 2021 | Susan M Diamond listed as Chief Financial Officer (previously Segment President, Home Bus.) in SEC filings |
| Jun 1, 2021 | Brian A Kane reported in an SEC filing no longer being Chief Financial Officer |
| Apr 22, 2021 | Frank Bisignano reported in an SEC filing no longer being a director |
| Feb 17, 2021 | Marcy S Klevorn became a director |
| Feb 17, 2021 | Jorge S. Mesquita became a director |
| Dec 17, 2020 | William H Shrank first listed as a director in an SEC filing |
| Sep 4, 2020 | Raquel C. Bono became a director |
| Aug 11, 2020 | Webster Roy Dunbar reported in an SEC filing no longer being a director |
| Feb 26, 2020 | William H Shrank listed as Chief Med & Corp Affairs Off. (previously Chief Medical Officer) in SEC filings |
| Feb 19, 2020 | Wayne A.I. Frederick became a director |
| Feb 19, 2020 | John W Garratt became a director |
| Dec 31, 2019 | Elizabeth D Bierbower reported in an SEC filing no longer being Strategic Advisor |
| Dec 31, 2019 | Brian P. LeClaire reported in an SEC filing no longer being Strategic Advisor |
| Dec 17, 2019 | William Kevin Fleming listed as Seg Pres, Clin & Phm Solutions (previously Seg President, Healthcare Svcs) in SEC filings |
| Dec 16, 2019 | Joseph C Ventura listed as Chief Legal Officer (previously Chief Legal Officer & Corp Sec) in SEC filings |
| Dec 13, 2019 | Vishal Agrawal listed as Chief Strat & Corp Dev Officer (previously Chief Strategy Officer) in SEC filings |
| Dec 10, 2019 | Timothy S. Huval listed as Chief Administrative Officer (previously Chief HR Officer) in SEC filings |
| Dec 10, 2019 | Elizabeth D Bierbower listed as Strategic Advisor (previously Segment President) in SEC filings |
| Dec 2, 2019 | Jody L Bilney reported in an SEC filing no longer being Chief Consumer Officer |
| Oct 15, 2019 | Karen B DeSalvo reported in an SEC filing no longer being a director |
| Sep 20, 2019 | Karen Katz became a director |
| Sep 4, 2019 | Heather Cox listed as Chief Dig Health & Analyt Off. (previously Chief Digital & Analytics Off.) in SEC filings |
| Aug 26, 2019 | Brian P. LeClaire listed as Strategic Advisor (previously Chief Information Officer) in SEC filings |
| Aug 19, 2019 | Christopher H. Hunter listed as Seg Pres. Gr. & Military Bus. (previously Seg President, Group Business) in SEC filings |
| Aug 6, 2019 | Samir Deshpande listed as Chief Tech & Risk Officer (previously Chief Risk Officer) in SEC filings |
| Jul 15, 2019 | Susan M Diamond became Segment President, Home Bus. |
| Apr 19, 2019 | William Mitchell reported in an SEC filing no longer being a director |
| Apr 19, 2019 | David Nash reported in an SEC filing no longer being a director |
| Apr 1, 2019 | William H Shrank became Chief Medical Officer |
| Apr 1, 2019 | Roy A Beveridge reported in an SEC filing no longer being Chief Medical Officer |
| Feb 21, 2019 | Joseph C Ventura became Chief Legal Officer & Corp Sec |
| Feb 1, 2019 | M Todoroff Christopher reported in an SEC filing no longer being Chief Legal Officer |
| Feb 1, 2019 | Heidi S Margulis reported in an SEC filing no longer being Chief Corp. Affairs Officer |
| Dec 18, 2018 | Elizabeth D Bierbower listed as Segment President (previously Segment President, Group Bus.) in SEC filings |
| Dec 18, 2018 | Cynthia H Zipperle listed as SVP, Chief Acct Officer & Cont (previously SVP, Chief Accounting Officer) in SEC filings |
| Dec 10, 2018 | Vishal Agrawal became Chief Strategy Officer |
| Sep 17, 2018 | Christopher H. Hunter listed as Seg President, Group Business (previously Chief Strategy Officer) in SEC filings |
| Aug 27, 2018 | Heather Cox became Chief Digital & Analytics Off. |
| Feb 21, 2018 | William Kevin Fleming listed as Seg President, Healthcare Svcs (previously President, Hlthcare Svc Sgmt) in SEC filings |
| Feb 21, 2018 | Timothy S. Huval listed as Chief HR Officer (previously Senior VP & Chief HR Officer) in SEC filings |
| Feb 21, 2018 | Roy A Beveridge listed as Chief Medical Officer (previously Sr. VP & Chief Medical Officer) in SEC filings |
| Feb 21, 2018 | M Todoroff Christopher listed as Chief Legal Officer (previously Sr. VP and General Counsel) in SEC filings |
| Feb 21, 2018 | Jody L Bilney listed as Chief Consumer Officer (previously SVP & Chief Consumer Officer) in SEC filings |
| Feb 21, 2018 | Heidi S Margulis listed as Chief Corp. Affairs Officer (previously Senior V.P. -Corporate Affairs) in SEC filings |
| Feb 21, 2018 | Elizabeth D Bierbower listed as Segment President, Group Bus. (previously President, Group Segment) in SEC filings |
| Feb 21, 2018 | Cynthia H Zipperle listed as SVP, Chief Accounting Officer (previously Vice President, CAO,Controller) in SEC filings |
| Feb 21, 2018 | Christopher H. Hunter listed as Chief Strategy Officer (previously SVP and Chief Strategy Officer) in SEC filings |
| Feb 21, 2018 | Brian P. LeClaire listed as Chief Information Officer (previously SVP & Chief Information Off.) in SEC filings |
| Feb 21, 2018 | Brian A Kane listed as Chief Financial Officer (previously SVP & Chief Financial Officer) in SEC filings |
| Dec 19, 2017 | Joseph William Jasser reported in an SEC filing no longer being President, Care Delivery |
| Nov 10, 2017 | Karen B DeSalvo became a director |
| Aug 17, 2017 | Frank Bisignano became a director |
| Jul 17, 2017 | Samir Deshpande became Chief Risk Officer |
| Jun 30, 2017 | Christopher E Kay reported in an SEC filing no longer being SVP & Chief Innovation Officer |
| Apr 3, 2017 | James E Murray reported in an SEC filing no longer being EVP & COO |
| Mar 10, 2017 | Elizabeth D Bierbower first listed as President, Group Segment in an SEC filing |
| Mar 1, 2017 | William Kevin Fleming became President, Hlthcare Svc Sgmt |
| Mar 1, 2017 | Timothy Alan Wheatley became Segment President, Retail |
| Mar 1, 2017 | Joseph William Jasser became President, Care Delivery |
| Feb 22, 2017 | Bruce D Broussard first listed as a director in an SEC filing |
Not reported recently (3)
- Vishal Agrawal · Last reported as Chief Strat & Corp Dev Officer in an SEC filing dated Feb 25, 2025
- Brad D Smith · Last reported as a director in an SEC filing dated Jan 3, 2025
- Samir Deshpande · Last reported as Chief Information Officer in an SEC filing dated Dec 17, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
HUM Proposed Insider Sales (Form 144)
Latest: 2025-04-08
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-04-08 | Diamond Susan M | Former Chief Financial Officer | 10,959 | $2.73M | 2025-04-08 | Charles Schwab & Co. Inc. | — | EDGAR |
| 2025-02-24 | Huval Timothy S. | Former Chief Administrative Officer | 1,247 | $322.4K | 2025-02-24 | Charles Schwab | — | EDGAR |
| 2024-12-31 | Huval Timothy S. | Officer | 3,703 | $938.4K | 2024-12-31 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2024-12-06 | William K. Fleming | Officer | 8,661 | $2.45M | 2024-12-06 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2023-05-16 | James J. O'Brien | Former Board of Directors | 11,425 | $5.97M | 2023-05-16 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2023-05-04 | Diamond Susan M | Officer | 4,156 | $2.21M | 2023-05-04 | Charles Schwab & Co. Inc. | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-06-01
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-06-01 | 0000049071-26-000027 | EDGAR |
| 2026-05-19 | 0000049071-26-000025 | EDGAR |
| 2026-04-29 | 0000049071-26-000021 | EDGAR |
| 2026-04-20 | 0000049071-26-000015 | EDGAR |
| 2026-04-10 | 0000049071-26-000013 | EDGAR |
| 2026-03-09 | 0001628280-26-016031 | EDGAR |
| 2026-03-02 | 0000049071-26-000011 | EDGAR |
| 2026-02-11 | 0000049071-26-000005 | EDGAR |
| 2025-12-16 | 0000049071-25-000061 | EDGAR |
| 2025-12-01 | 0000049071-25-000059 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-19 | 0000049071-26-000009 | EDGAR |
| 2025-02-20 | 0000049071-25-000007 | EDGAR |
| 2024-02-15 | 0000049071-24-000012 | EDGAR |
| 2023-02-16 | 0000049071-23-000011 | EDGAR |
| 2022-02-17 | 0000049071-22-000017 | EDGAR |
| 2021-02-18 | 0000049071-21-000039 | EDGAR |
| 2020-02-20 | 0000049071-20-000032 | EDGAR |
| 2019-02-21 | 0000049071-19-000023 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000049071-26-000023 | EDGAR |
| 2025-11-05 | 0000049071-25-000057 | EDGAR |
| 2025-07-30 | 0000049071-25-000042 | EDGAR |
| 2025-04-30 | 0000049071-25-000023 | EDGAR |
| 2024-10-30 | 0000049071-24-000055 | EDGAR |
| 2024-07-31 | 0000049071-24-000040 | EDGAR |
| 2024-04-24 | 0000049071-24-000023 | EDGAR |
| 2023-11-01 | 0000049071-23-000064 | EDGAR |
| 2023-08-02 | 0000049071-23-000049 | EDGAR |
| 2023-04-26 | 0000049071-23-000025 | EDGAR |
ETF Holders
297 ETFs hold HUM
25 shown · $8.04B total exposure · 0.11% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.06% | $1.5B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.07% | $1.2B | — | 2026-09-30 |
| 3 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.45% | $981.1M | — | 2026-09-30 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.08% | $682.4M | $890.4B | 2026-10-20 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.08% | $633.1M | $818.4B | 2026-10-20 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.17% | $436.5M | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.79% | $374.1M | $47.5B | 2026-10-20 |
| 8 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.78% | $286.1M | — | 2026-09-30 |
| 9 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.38% | $215.0M | $57.3B | 2026-10-20 |
| 10 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.21% | $209.7M | — | 2026-10-20 |
| 11 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.19% | $186.4M | — | 2026-09-30 |
| 12 | EAGL Eagle Capital Select Equity ETF | Nport | 4.04% | $172.0M | — | 2026-06-30 |
| 13 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.08% | $141.5M | $183.5B | 2026-10-20 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.64% | $140.0M | — | 2026-09-30 |
| 15 | JEPI JPMorgan Equity Premium Income ETF | JPMorgan | 0.25% | $115.6M | $46.0B | 2026-10-21 |
| 16 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.14% | $114.7M | $84.5B | 2026-10-20 |
| 17 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.17% | $85.3M | $50.4B | 2026-10-20 |
| 18 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.32% | $81.1M | — | 2026-05-31 |
| 19 | RWL Invesco S&P 500 Revenue ETF | Invesco | 0.77% | $79.0M | — | 2026-10-20 |
| 20 | SCHG Schwab U.S. Large-Cap Growth ETF | Nport | 0.13% | $78.4M | — | 2026-05-31 |
| 21 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.50% | $78.1M | $15.6B | 2026-10-20 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.09% | $77.6M | — | 2026-10-20 |
| 23 | MTUM iShares MSCI USA Momentum Factor ETF | iShares (BlackRock) | 0.41% | $76.4M | $18.9B | 2026-10-20 |
| 24 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.82% | $69.8M | $8.5B | 2026-10-20 |
| 25 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.07% | $66.6M | $97.4B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
40.17
TTM Diluted EPS
$10.59
TTM Revenue
$145.14B
TTM Net Income
$1.28B
TTM Op. Cash Flow
$2.54B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $40.87B | $694.00M | $5.73 | $1.97B |
| Q1 '26 | 2026-03-31 | $39.65B | $1.19B | $9.83 | $1.25B |
| Q4 '25 | 2025-12-31 | $32.38B | $-796.00M | $-6.59 | $-1.65B |
| Q3 '25 | 2025-09-30 | $32.25B | $195.00M | $1.62 | $971.00M |
| Q2 '25 | 2025-06-30 | $32.39B | $545.00M | $4.51 | $1.27B |
| Q1 '25 | 2025-03-31 | $32.11B | $1.24B | $10.30 | $331.00M |
| Q4 '24 | 2024-12-31 | $28.92B | $-693.00M | $-5.74 | $-528.00M |
| Q3 '24 | 2024-09-30 | $29.05B | $480.00M | $3.98 | $1.86B |
| Q2 '24 | 2024-06-30 | $29.54B | $679.00M | $5.62 | $1.21B |
| Q1 '24 | 2024-03-31 | $29.61B | $741.00M | $6.11 | $423.00M |
| Q4 '23 | 2023-12-31 | $26.17B | $-541.00M | $-4.26 | $-7.13B |
| Q3 '23 | 2023-09-30 | $26.11B | $832.00M | $6.71 | $1.25B |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
40.17
P/B
2.67
P/S
0.35
EV/EBITDA
19.93
EV/Sales
0.40
ROE
6.6%
ROA
2.2%
Div Yield
0.84%
FCF Yield
4.94%
Debt/Equity
0.74
Current Ratio
—
Market Cap
$51.41B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.79M
SI % of Float
2.33%
Days to Cover
2.24
Short Vol Ratio
36.4%
Free Float
119.88M
Float %
99.8%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14